Leukotriene B4 potentiates the expression and release of Fc epsilon RII/CD23, and proliferation and differentiation of human B lymphocytes induced by IL-4.
This study documents the influence of leukotriene (LT) B4 on human B lymphocyte responses. Incubation of freshly isolated B lymphocytes with LTB4, but not LTC4, induced a slight but significant, time- and dose-dependent increase in the surface expression of Fc epsilon RII/CD23 and class II MHC Ag and in the release of soluble CD23. These changes were maximal at 10 nM LTB4 after an incubation period of 48 h. When B lymphocytes were preactivated in vitro with Staphylococcus aureus Cowan strain I (SAC), neither LTB4 nor LTC4 was able to promote proliferation and/or IgG and IgM secretion. In contrast, when resting B lymphocytes were stimulated with a suboptimal concentration (3 U/ml) of IL-4, LTB4, but not LTC4, potentiated both the Fc epsilon RII/CD23 and the class II MHC antigen expression, and the release of soluble CD23 in a dose-dependent manner, without affecting the kinetics of these responses. Furthermore, LTB4, but not LTC4, amplified both the proliferative response and the IgG and IgM secretion induced by addition of a suboptimal dose of IL-4 (3 U/ml) to SAC-preactivated B lymphocytes. Again, LTB4 did not modify the kinetics of the proliferative response promoted by IL-4. Although LTB4 potentiated IL-4-induced IgG and IgM secretion from SAC-activated B lymphocytes, no production of IgE was observed. These data indicate that LTB4 could play a regulatory role in the modulation of IL-4-induced signaling in human B lymphocytes.
Dugas
B
B
Department of Immunology, Institut Henri Beaufour, Les Ulis, France.
Paul-Eugene
N
N
Cairns
J
J
Gordon
J
J
Calenda
A
A
Mencia-Huerta
J M
JM
Braquet
P
P
D015703:Antigens, CD / Q000096:biosynthesis*; D000944:Antigens, Differentiation, B-Lymphocyte / Q000096:biosynthesis* / Q000378:metabolism; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D002454:Cell Differentiation / Q000187:drug effects; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D007136:Immunoglobulins / Q000096:biosynthesis; D015847:Interleukin-4 / Q000494:pharmacology*; D007975:Leukotriene B4 / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D011961:Receptors, Fc / Q000096:biosynthesis* / Q000378:metabolism; D017455:Receptors, IgE; D013189:SRS-A / Q000494:pharmacology
D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D000949:Histocompatibility Antigens Class II; D007136:Immunoglobulins; D011961:Receptors, Fc; D017455:Receptors, IgE; D013189:SRS-A; D007975:Leukotriene B4; D015847:Interleukin-4